p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects. - Wikidata - wikimedia - TriplyDB

p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

http://www.wikidata.org/entity/Q37660709

about

Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?

P2860

Q44877659-08DD8AF5-9EB0-4303-9B6D-FBDE006C64CD

P2860

p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

http://www.wikidata.org/entity/Q37660709

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@en

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@nl

type

label

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@en

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@nl

prefLabel

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@en

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@nl

P1433

Q37660709-92476C67-891C-4C67-B8DF-6396C333D8F6

P1476

Q37660709-A843B471-C32B-4975-92DC-DE41F2D0DB06

P2093

Q37660709-2E32F773-9A4D-49AA-B5C3-509BA07327C0

Q37660709-30AC33EF-AB3E-41DF-81F3-C84F6768AB10

Q37660709-4341EACB-8BC5-493C-B129-43089B310FF5

Q37660709-44B96D01-6336-44BC-BCD6-AD586A7B7198

Q37660709-4BF7C308-41FE-4117-A6BE-61BDC10AD970

Q37660709-5AC69E7B-0C52-4F20-988A-215991B1AC0E

Q37660709-7D050460-FCB2-45B7-86B4-B4057C648971

Q37660709-A0F328E1-C809-4342-98CE-10F8C45AEC37

Q37660709-B72E4D8A-3B7F-448B-85E3-E2DAAF9AF20C

Q37660709-B8D5C889-FABE-4B49-96F6-E4325CD8EAEB

P2860

Q37660709-038EC534-294D-4512-8621-A260E2364ABF

Q37660709-04566135-6798-4190-B24D-F98B20B56C1A

Q37660709-113E9B55-B811-4A2B-97CF-B8D478BB6B1E

Q37660709-165C364A-E52A-4AB8-87E8-18DC88C3B0E4

Q37660709-21ABD643-A41A-44F8-9DDA-0E4533613993

Q37660709-22A9F078-548E-450C-8316-0BD972AD5EA0

Q37660709-2AC393C8-CC05-4EF9-BA86-C19862546E33

Q37660709-3CEC7C14-D326-465A-A553-ECE9C1CF2889

Q37660709-426E6CB4-2113-4DDC-BB22-996176AA9085

Q37660709-5122E456-08CF-4A3F-B52F-7CC1C9751EA8

P304

Q37660709-39F969B2-B226-443E-86D0-0639372E3C49

P31

Q37660709-6346BD4F-D74F-4FFA-ADF2-8A0EEF5B49A2

P356

Q37660709-6F162132-5801-49DC-B804-DB2F419ED8C2

P433

Q37660709-DB09BB0E-0A77-4CF2-84C3-744DE461206C

P478

Q37660709-2BB0E972-1378-4A9F-B033-7FED0140E14F

P577

Q37660709-EF6BC802-B1E6-46AD-88CB-B689E0AF060E

P698

Q37660709-D292FD62-6F55-4349-8FBD-D6F5AAE135D7

P932

Q37660709-4D07BAC4-5E5F-4A48-92C7-45BDF91E6685

P356

P1433

CPT: pharmacometrics & systems pharmacology

P1476

p16INK4a , a Senescence Marker ...... tion in HIV-Infected Subjects.

@en

P2093

A Forrest

http://www.w3.org/2001/XMLSchema#string

C R Trezza

http://www.w3.org/2001/XMLSchema#string

C Sykes

http://www.w3.org/2001/XMLSchema#string

C Torrice

http://www.w3.org/2001/XMLSchema#string

Hma Prince

http://www.w3.org/2001/XMLSchema#string

J B Dumond

http://www.w3.org/2001/XMLSchema#string

J W Collins

http://www.w3.org/2001/XMLSchema#string

K B Patterson

http://www.w3.org/2001/XMLSchema#string

M L Cottrell

http://www.w3.org/2001/XMLSchema#string

N E Sharpless

http://www.w3.org/2001/XMLSchema#string

P2860

Frailty in older adults: evidence for a phenotype

Prediction of creatinine clearance from serum creatinine

Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics.

The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

P304

120-127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12150

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28019088

http://www.w3.org/2001/XMLSchema#string

P932

5321809

http://www.w3.org/2001/XMLSchema#string